This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
04/29/16 - 12:34:24 PM ET (BATS BZX Real-time Price)
Div Yield: --
STML Day's Range
STML 52 Week Range
STML Business Summary
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States.View STML
Stemline Therapeutics Inc - STML - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Stemline Therapeutics Inc as a
Sell with a ratings score of D.
Report Snippet: We rate STEMLINE THERAPEUTICS INC (STML) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.